Pfizer (PFE) is drawing attention as its dividend yield climbs to an attractive 6.4%, raising questions about the sustainability of its payout amidst recent stock performance challenges. Following a significant drop in revenue and earnings linked to the decline of its COVID-19 business, Pfizer’s stock has rebounded 25% over the past year. This resurgence comes as investors seek stability in blue-chip dividend payers amid volatile market conditions.

The company’s future may hinge on its robust phase 3 pipeline, which includes promising candidates like PF’4404, an investigational cancer treatment, and MET097i, a weight management therapy showing potential advantages over existing options. Successful outcomes from these late-stage studies could catalyze further stock appreciation and bolster Pfizer’s ability to maintain its dividend, even as it faces headwinds like the loss of exclusivity for key products.

For market professionals, Pfizer’s combination of a high dividend yield and a promising drug pipeline positions it as a compelling option for income-focused investors looking for stability amidst market uncertainty.

Source: fool.com